Proton Pump Inhibitors Use and Risk of Preeclampsia: A
Meta-Analysis

J 2022

Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis

HUSSAIN, Mohammad Salman, A. SINGH, B. ANTONY, Jitka KLUGAROVÁ, M. H. MURAD et. al.

Základní údaje

Originální název

Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis

Autoři

HUSSAIN, Mohammad Salman (356 Indie, garant, domácí), A. SINGH, B. ANTONY, Jitka KLUGAROVÁ (203 Česká republika, domácí), M. H. MURAD, A. S. JAYRAJ, Alena LANGAUFOVÁ (203 Česká republika, domácí) a Miloslav KLUGAR (203 Česká republika, domácí)

Vydání

Journal of Clinical Medicine, Basel, MDPI, 2022, 2077-0383

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.900

Kód RIV

RIV/00216224:14110/22:00126538

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/jcm11164675

UT WoS

000846554700001

Klíčová slova anglicky

hypertension; preeclampsia; proton pump inhibitors; PPIs; pregnancy; meta-analysis

Štítky

14119612, 14119613, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 1. 2023 13:38, Mgr. Tereza Miškechová

Anotace

V originále

Evidence from preclinical studies suggests a preventive effect of proton pump inhibitors (PPIs) in preeclampsia. Recently, several epidemiological studies have described a conflicting association between the use of PPIs during pregnancy and preeclampsia risk. This study aimed to evaluate the association between PPI use and the risk of preeclampsia. We searched databases, including MEDLINE, Embase, Scopus, Web of Science Core Collection, Emcare, CINAHL, and the relevant grey literature from inception until 13 September 2021. Studies reporting the preeclampsia risk with the use of PPIs were eligible for inclusion. Literature screening, data extraction, and the risk of bias assessment were performed independently by two investigators. Random-effect meta-analysis was performed to generate relative risks (RR) and 95% confidence intervals (CI). The risk of preeclampsia and preterm preeclampsia among women receiving PPIs during pregnancy were the primary outcomes of interest. This meta-analysis comprised three studies involving 4,877,565 pregnant women, of whom 119,017 were PPI users. The included studies were judged to have a low risk of bias. The risk of preeclampsia among pregnant women who received PPIs anytime during pregnancy was significantly increased (RR 1.27 (95% CI: 1.23–1.31)), although the increase was trivial in absolute terms (2 per 1000). The subgroup analysis revealed that the risk was increased in each of the three trimesters. The risk of preterm preeclampsia among pregnant women receiving PPIs anytime during pregnancy was not significantly increased (RR 1.04 (95% CI: 0.70–1.55)). The certainty evaluated by GRADE in these estimates was low. PPI use may be associated with a trivial increase in the risk of preeclampsia in pregnant women. There is no evidence supporting that PPI use decreases the risk of preeclampsia or preterm preeclampsia.

Návaznosti

EF18_053/0016952, projekt VaV

Název: Postdoc2MUNI

LTC20031, projekt VaV

Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST

Citovat

HUSSAIN, Mohammad Salman, A. SINGH, B. ANTONY, Jitka KLUGAROVÁ, M. H. MURAD, A. S. JAYRAJ, Alena LANGAUFOVÁ a Miloslav KLUGAR. Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis. Journal of Clinical Medicine. Basel: MDPI, 2022, roč. 11, č. 16, s. 1-15. ISSN 2077-0383. Dostupné z: https://dx.doi.org/10.3390/jcm11164675.

@article{2213959,
   author = {Hussain, Mohammad Salman and Singh, A. and Antony, B. and Klugarová, Jitka and Murad, M. H. and Jayraj, A. S. and Langaufová, Alena and Klugar, Miloslav},
   article_location = {Basel},
   article_number = {16},
   doi = {http://dx.doi.org/10.3390/jcm11164675},
   keywords = {hypertension; preeclampsia; proton pump inhibitors; PPIs; pregnancy; meta-analysis},
   language = {eng},
   issn = {2077-0383},
   journal = {Journal of Clinical Medicine},
   title = {Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis},
   url = {https://www.mdpi.com/2077-0383/11/16/4675},
   volume = {11},
   year = {2022}
}

TY  - JOUR
ID  - 2213959
AU  - Hussain, Mohammad Salman - Singh, A. - Antony, B. - Klugarová, Jitka - Murad, M. H. - Jayraj, A. S. - Langaufová, Alena - Klugar, Miloslav
PY  - 2022
TI  - Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis
JF  - Journal of Clinical Medicine
VL  - 11
IS  - 16
SP  - 1-15
EP  - 1-15
PB  - MDPI
SN  - 20770383
KW  - hypertension
KW  - preeclampsia
KW  - proton pump inhibitors
KW  - PPIs
KW  - pregnancy
KW  - meta-analysis
UR  - https://www.mdpi.com/2077-0383/11/16/4675
N2  - Evidence from preclinical studies suggests a preventive effect of proton pump inhibitors (PPIs) in preeclampsia. Recently, several epidemiological studies have described a conflicting association between the use of PPIs during pregnancy and preeclampsia risk. This study aimed to evaluate the association between PPI use and the risk of preeclampsia. We searched databases, including MEDLINE, Embase, Scopus, Web of Science Core Collection, Emcare, CINAHL, and the relevant grey literature from inception until 13 September 2021. Studies reporting the preeclampsia risk with the use of PPIs were eligible for inclusion. Literature screening, data extraction, and the risk of bias assessment were performed independently by two investigators. Random-effect meta-analysis was performed to generate relative risks (RR) and 95% confidence intervals (CI). The risk of preeclampsia and preterm preeclampsia among women receiving PPIs during pregnancy were the primary outcomes of interest. This meta-analysis comprised three studies involving 4,877,565 pregnant women, of whom 119,017 were PPI users. The included studies were judged to have a low risk of bias. The risk of preeclampsia among pregnant women who received PPIs anytime during pregnancy was significantly increased (RR 1.27 (95% CI: 1.23–1.31)), although the increase was trivial in absolute terms (2 per 1000). The subgroup analysis revealed that the risk was increased in each of the three trimesters. The risk of preterm preeclampsia among pregnant women receiving PPIs anytime during pregnancy was not significantly increased (RR 1.04 (95% CI: 0.70–1.55)). The certainty evaluated by GRADE in these estimates was low. PPI use may be associated with a trivial increase in the risk of preeclampsia in pregnant women. There is no evidence supporting that PPI use decreases the risk of preeclampsia or preterm preeclampsia.
ER  -

HUSSAIN, Mohammad Salman, A. SINGH, B. ANTONY, Jitka KLUGAROVÁ, M. H. MURAD, A. S. JAYRAJ, Alena LANGAUFOVÁ a Miloslav KLUGAR. Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis. \textit{Journal of Clinical Medicine}. Basel: MDPI, 2022, roč.~11, č.~16, s.~1-15. ISSN~2077-0383. Dostupné z: https://dx.doi.org/10.3390/jcm11164675.

Podrobný výpis o publikaci